Genzyme General Newswire (Page 2)

Comprehensive Real-Time News Feed for Genzyme General. (Page 2)

Results 21 - 40 of 512 in Genzyme General

  1. Biogen's new MS drug to cost $62,036 a yearRead the original story w/Photo

    Friday Oct 3 | Boston.com

    Cambridge biotech Biogen Idec Inc. said Friday it will charge $62,036 per patient for a year's treatment with its newly approved multiple sclerosis drug Plegridy. The list price of Plegridy, a new type of injectable drug that treats adults with the most common form of MS, is identical to that of Biogen Idec's original injectable, Avonex, which is still on the market.

    Comment?

  2. Veracyte, Inc. To Host Investor Day On October 9, 2014Read the original story

    Thursday Oct 2 | BioSpace

    The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com . Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download.

    Comment?

  3. A Look At Exact Sciences Corporation's StockRead the original story w/Photo

    Wednesday Oct 1 | Benzinga

    The institutions held about 96 percent of the company's stock and that amount had increased by almost 19 percent quarter over quarter. This makes Exact Sciences a stock worth considering when it comes to strong biotech names that investors and traders may want to add to their portfolio.

    Comment?

  4. Genzyme Corporation Announces Winners Of Patient Advocacy Leadership (PAL) AwardsRead the original story

    Wednesday Oct 1 | BioSpace

    Genzyme, a Sanofi company , today announced the recipients of the 2014 Genzyme Patient Advocacy Leadership Awards. This global grant program supports innovative projects by non-profit organizations in disease awareness and education, community mobilization, non-profit development and good governance activities, patient care and support programs.

    Comment?

  5. Genzyme Announces Winners of Patient Advocacy Leadership (PAL) AwardsRead the original story

    Wednesday Oct 1 | PressReleasePoint

    Genzyme , a Sanofi company , today announced the recipients of the 2014 Genzyme Patient Advocacy Leadership Awards. This global grant program supports innovative projects by non-profit organizations in disease awareness and education, community mobilization, non-profit development and good governance activities, patient care and support programs.

    Comment?

  6. Baxter to open new research center in Kendall SquareRead the original story w/Photo

    Monday Sep 29 | Boston.com

    Health care giant Baxter International Inc. said Monday it is leasing about 200,000 square feet of office space in the heart of Cambridge's Kendall Square to open a biopharmaceutical research center that will employ at least 400 people. Baxter, based in the Chicago suburb of Deerfield, Ill., has signed a 12-year lease at 650 East Kendall St., a building owned by a joint venture of BioMed Realty Trust and Prudential Real Estate Investors.

    Comment?

  7. Court Report - September 2014 #6Read the original story w/Photo

    Monday Sep 29 | JD Supra

    Cadence Pharmaceuticals Inc. et al. v. InnoPharma Licensing LLC et al. 1:14-cv-01225; filed September 24, 2014 in the District Court of Delaware Infringement of U.S. Patent Nos.

    Comment?

  8. Dr. Alan E. Smith , Former Chief Scientific Officer Of Genzyme...Read the original story

    Monday Sep 29 | BioSpace

    ImmuneXcite, Inc., a biopharmaceutical company focused on developing a next generation immunotherapy platform to generate new targeted immunotherapies for cancer employing a unique neutrophils-initiated immune response, today announced that Dr. Alan E. Smith CBE, FRS, Ph.D., has joined the Company's Scientific Advisory Board . Dr. Smith is joining an esteemed group of scientists including Prof.

    Comment?

  9. Dr. Alan E. Smith, Former Chief Scientific Officer of Genzyme, Joins...Read the original story

    Monday Sep 29 | Business Wire

    ImmuneXcite, Inc., a biopharmaceutical company focused on developing a next generation immunotherapy platform to generate new targeted immunotherapies for cancer employing a unique neutrophils-initiated immune response, today announced that Dr. Alan E. Smith CBE, FRS, Ph.D., has joined the Company's Scientific Advisory Board . Dr. Smith is joining an esteemed group of scientists including Prof.

    Comment?

  10. Long-Term Bears Take Aim at MannKind CorporationRead the original story

    Thursday Sep 25 | SchaeffersResearch.com

    MannKind Corporation has held up well today, despite the broad-market headwinds. At last check, the shares were 0.8% higher at $6.13, following yesterday's news that the drugmaker has closed a licensing deal with Sanofi SA .

    Comment?

  11. NASDAQ Dips 1.5%; HB Fuller Shares Decline On Downbeat ResultsRead the original story w/Photo

    Thursday Sep 25 | Benzinga

    Midway through trading Thursday, the Dow traded down 1.14 percent to 17,013.29 while the NASDAQ tumbled 1.54 percent to 4,485.16. The S&P also fell, dropping 1.13 percent to 1,975.65.

    Comment?

  12. BioMarin Pharmaceutical Inc. Release: FDA Receives Paragraph IV...Read the original story

    Thursday Sep 25 | BioSpace

    BioMarin Pharmaceutical Inc. today announced that a Paragraph IV Certification Notice Letter was submitted to the US Food and Drug Administration in connection with an Abbreviated New Drug Application to the FDA for approval to market a generic version of KUVANA Tablets, although it has not yet received notice of the certification. BioMarin has 8 patents listed in the FDA Orange Book with expiration dates between 2024 and 2026.

    Comment?

  13. Top IND Pitfalls & How to Avoid ThemRead the original story

    Wednesday Sep 24 | Laboratory Network .com

    Your team has been working around the clock to meet your corporate objective of an IND submission in Q4 of this year, but you've had some delays. You're still waiting on the final GLP toxicology study report from your CRO, the Certificate of Analysis from your CMO of the GMP run to supply the clinical trial, and the final version of investigational brochure from your contract medical writer.

    Comment?

  14. Genzyme Corporation Collaborates On Gene Therapy For Rare Disease That Causes Childhood BlindnessRead the original story

    Wednesday Sep 24 | BioSpace

    Genzyme, a Sanofi company , today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness. Leber congenital amaurosis type 1 is usually diagnosed in children who are less than a year old, and patients remain severely visually impaired for the rest of their lives.

    Comment?

  15. Genzyme Collaborates on Gene Therapy for Rare Disease that Causes Childhood BlindnessRead the original story

    Wednesday Sep 24 | Business Wire

    Genzyme , a Sanofi company , today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness. Leber congenital amaurosis type 1 is usually diagnosed in children who are less than a year old, and patients remain severely visually impaired for the rest of their lives.

    Comment?

  16. BioMarin Pharmaceutical Inc. To Attend Upcoming Investor ConferencesRead the original story

    Tuesday Sep 23 | BioSpace

    BioMarin Pharmaceutical Inc. , today announced that management will participate in the Jefferies Gene Therapy Summit on September 30th in Boston and in the Leerink Rare Disease Roundtable on October 1st in New York. To access a live webcast of the Leerink presentation, please visit the investor section of the BioMarin website, www.BMRN.com .

    Comment?

  17. 'Globalization is Not Americanization' When It Comes to HealthcareRead the original story w/Photo

    Monday Sep 22 | Medical Device/Diagnostic Ind.

    Nearly every major medical device manufacturer - if not all of them - have identified the "emerging markets" as their principal source of revenue growth in the coming years. But tapping into that current will take a deft hand and keen eye as what emerges from these countries may not be the acute-care-based system seen in developed countries.

    Comment?

  18. Rare disease drug pioneer at Genzyme turns focus to schizophreniaRead the original story w/Photo

    Monday Sep 22 | Business Journal

    Rogerio Vivaldi, CEO of Minerva Neurosciences, discusses his patient-centered vision for the Cambridge drug company, which is developing drugs to treat schizophrenia, depression, insomnia and Parkinson's disease. After 20 years at local drug giant Genzyme , Vivaldi was head of that company's unparalleled rare diseases unit, reporting directly to CEO David Meeker .

    Comment?

  19. Sanofi Announces Upcoming Launch of MyStar ConnectRead the original story

    Sep 17, 2014 | Hispanic Business

    MyStar Connect will support HCPs in the delivery of individualised patient care by providing necessary insights and analysis to optimise diabetes management. The new software is part of the MyStar portfolio consisting of medical devices, support services and guidance and connects to , our integrated care strategy, rather than just developing drugs alone, aims to support people with diabetes holistically, improving patient experiences and outcomes, " said Pierre Chancel, Senior Vice President, Global Diabetes, ' s long term commitment to improve diabetes care, helping to streamline and simplify the way HCPs can access and visualise their patients ' blood glucose data.

    Comment?

  20. Sanofi Announces Upcoming Launch of MyStar ConnectARead the original story

    Sep 17, 2014 | Sys-Con Media

    MyStar ConnectA will support HCPs in the delivery of individualised patient care by providing necessary insights and analysis to optimise diabetes management. The new software is part of the MyStarA portfolio consisting of medical devices, support services and guidance and connects to Sanofi's BGStarA and MyStar ExtraA blood glucose meters.

    Comment?